{"analyses":[{"ciLowerLimit":"-19.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"20.86","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8817","paramType":"Difference in Response Rates","paramValue":"0.69","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"7.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"44.74","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0061","paramType":"Difference in Response Rates","paramValue":"27.50","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.18","upperLimit":"78.80","value":"64.1"},{"groupId":"OG001","lowerLimit":"46.94","upperLimit":"77.88","value":"63.4"},{"groupId":"OG002","lowerLimit":"27.04","upperLimit":"59.11","value":"42.5"},{"groupId":"OG003","lowerLimit":"5.71","upperLimit":"29.84","value":"15.0"},{"groupId":"OG004","lowerLimit":"40.78","upperLimit":"84.61","value":"65.0"},{"groupId":"OG005","lowerLimit":"14.59","upperLimit":"56.97","value":"33.3"},{"groupId":"OG006","lowerLimit":"27.63","upperLimit":"46.71","value":"36.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"106"}],"units":"Participants"}],"description":"CR was assessed by investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \\> mediastinum but ≤ liver; 4=uptake moderately \\> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG000","title":"Arm A (Phase II Randomization): Pola+BR in FL"},{"description":"Participants with FL received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6.","id":"OG001","title":"Arm B (Phase II Randomization): BR in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG002","title":"Arm C (Phase II Randomization): Pola+BR in DLBCL"},{"description":"Participants with DLBCL received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6.","id":"OG003","title":"Arm D (Phase II Randomization): BR in DLBCL"},{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG004","title":"Arm E (Phase II Expansion): Pola+BG in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG005","title":"Arm F (Phase II Expansion): Pola+BG in DLBCL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG006","title":"Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment.","reportingStatus":"POSTED","timeFrame":"6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)","title":"Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}